Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Jun. 30, 2023 | Aug. 03, 2023 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Jun. 30, 2023 | |
Document Fiscal Year Focus | 2023 | |
Document Fiscal Period Focus | Q2 | |
Trading Symbol | KURA | |
Entity Registrant Name | KURA ONCOLOGY, INC. | |
Entity Central Index Key | 0001422143 | |
Entity Current Reporting Status | Yes | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Large Accelerated Filer | |
Entity Shell Company | false | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Common Stock, Shares Outstanding | 74,236,353 | |
Entity File Number | 001-37620 | |
Entity Tax Identification Number | 61-1547851 | |
Entity Address, Address Line One | 12730 High Bluff Drive | |
Entity Address, Address Line Two | Suite 400 | |
Entity Address, City or Town | San Diego | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 92130 | |
City Area Code | 858 | |
Local Phone Number | 500-8800 | |
Entity Interactive Data Current | Yes | |
Title of 12(b) Security | Common Stock, par value $0.0001 per share | |
Security Exchange Name | NASDAQ | |
Entity Incorporation, State or Country Code | DE | |
Document Quarterly Report | true | |
Document Transition Report | false |
Condensed Balance Sheets (Unaud
Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 49,124 | $ 51,802 |
Short-term investments | 427,855 | 386,183 |
Prepaid expenses and other current assets | 8,667 | 8,441 |
Total current assets | 485,646 | 446,426 |
Property and equipment, net | 2,253 | 2,540 |
Restricted cash | 210 | 210 |
Operating lease right-of-use assets | 2,933 | 3,842 |
Other long-term assets | 3,695 | 3,288 |
Total assets | 494,737 | 456,306 |
Current liabilities: | ||
Accounts payable and accrued expenses | 21,554 | 21,739 |
Current operating lease liabilities | 2,345 | 2,318 |
Total current liabilities | 23,899 | 24,057 |
Long-term debt, net | 9,244 | 9,158 |
Long-term operating lease liabilities | 1,455 | 2,548 |
Other long-term liabilities | 461 | 265 |
Total liabilities | 35,059 | 36,028 |
Stockholders'equity: | ||
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares issued and outstanding | ||
Common stock, $0.0001 par value; 200,000 shares authorized; 74,143 and 68,314 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | 7 | 7 |
Additional paid-in capital | 1,104,944 | 997,111 |
Accumulated other comprehensive loss | (5,222) | (8,032) |
Accumulated deficit | (640,051) | (568,808) |
Total stockholders'equity | 459,678 | 420,278 |
Total liabilities and stockholders'equity | $ 494,737 | $ 456,306 |
Condensed Balance Sheets (Una_2
Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares | Jun. 30, 2023 | Dec. 31, 2022 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 200,000,000 | 200,000,000 |
Common stock, shares issued | 74,143,000 | 68,314,000 |
Common stock, shares outstanding | 74,143,000 | 68,314,000 |
Condensed Statements of Operati
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Operating Expenses: | ||||
Research and development | $ 28,182 | $ 24,258 | $ 53,374 | $ 45,171 |
General and administrative | 11,821 | 11,075 | 23,195 | 22,944 |
Total operating expenses | 40,003 | 35,333 | 76,569 | 68,115 |
Other Income (Expense): | ||||
Interest and other income, net | 3,216 | 564 | 6,077 | 893 |
Interest expense | (387) | (751) | ||
Total other income, net | 2,829 | 564 | 5,326 | 893 |
Net Loss | $ (37,174) | $ (34,769) | $ (71,243) | $ (67,222) |
Net loss per share, basic | $ (0.53) | $ (0.52) | $ (1.03) | $ (1.01) |
Net loss per share, diluted | $ (0.53) | $ (0.52) | $ (1.03) | $ (1.01) |
Weighted average number of shares used in computing net loss per share, basic | 69,795 | 66,672 | 69,103 | 66,639 |
Weighted average number of shares used in computing net loss per share, diluted | 69,795 | 66,672 | 69,103 | 66,639 |
Comprehensive Loss: | ||||
Net loss | $ (37,174) | $ (34,769) | $ (71,243) | $ (67,222) |
Other comprehensive income (loss): | ||||
Unrealized gain (loss) on marketable securities and foreign currency | 674 | (1,167) | 2,810 | (6,026) |
Comprehensive Loss | $ (36,500) | $ (35,936) | $ (68,433) | $ (73,248) |
Condensed Statements of Stockho
Condensed Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands | Total | Common Stock | Additional Paid- In Capital | Accumulated Other Comprehensive Income (Loss) | Accumulated Deficit |
Beginning balance at Dec. 31, 2021 | $ 506,609 | $ 7 | $ 941,359 | $ (1,789) | $ (432,968) |
Beginning balance (in shares) at Dec. 31, 2021 | 66,572 | ||||
Share-based compensation expense | 6,650 | 6,650 | |||
Issuance of common stock under equity plans | 303 | 303 | |||
Issuance of common stock under equity plans, shares | 64 | ||||
Other comprehensive income (loss) | (4,859) | (4,859) | |||
Net loss | (32,453) | (32,453) | |||
Ending balance at Mar. 31, 2022 | 476,250 | $ 7 | 948,312 | (6,648) | (465,421) |
Ending balance (in shares) at Mar. 31, 2022 | 66,636 | ||||
Beginning balance at Dec. 31, 2021 | 506,609 | $ 7 | 941,359 | (1,789) | (432,968) |
Beginning balance (in shares) at Dec. 31, 2021 | 66,572 | ||||
Net loss | (67,222) | ||||
Ending balance at Jun. 30, 2022 | 449,491 | $ 7 | 957,489 | (7,815) | (500,190) |
Ending balance (in shares) at Jun. 30, 2022 | 66,838 | ||||
Beginning balance at Mar. 31, 2022 | 476,250 | $ 7 | 948,312 | (6,648) | (465,421) |
Beginning balance (in shares) at Mar. 31, 2022 | 66,636 | ||||
Share-based compensation expense | 6,508 | 6,508 | |||
Issuance of common stock under equity plans | 2,669 | 2,669 | |||
Issuance of common stock under equity plans, shares | 202 | ||||
Other comprehensive income (loss) | (1,167) | (1,167) | |||
Net loss | (34,769) | (34,769) | |||
Ending balance at Jun. 30, 2022 | 449,491 | $ 7 | 957,489 | (7,815) | (500,190) |
Ending balance (in shares) at Jun. 30, 2022 | 66,838 | ||||
Beginning balance at Dec. 31, 2022 | 420,278 | $ 7 | 997,111 | (8,032) | (568,808) |
Beginning balance (in shares) at Dec. 31, 2022 | 68,314 | ||||
Share-based compensation expense | 6,838 | 6,838 | |||
Issuance of common stock under equity plans, shares | 125 | ||||
Other comprehensive income (loss) | 2,136 | 2,136 | |||
Net loss | (34,069) | (34,069) | |||
Ending balance at Mar. 31, 2023 | 395,183 | $ 7 | 1,003,949 | (5,896) | (602,877) |
Ending balance (in shares) at Mar. 31, 2023 | 68,439 | ||||
Beginning balance at Dec. 31, 2022 | 420,278 | $ 7 | 997,111 | (8,032) | (568,808) |
Beginning balance (in shares) at Dec. 31, 2022 | 68,314 | ||||
Net loss | (71,243) | ||||
Ending balance at Jun. 30, 2023 | 459,678 | $ 7 | 1,104,944 | (5,222) | (640,051) |
Ending balance (in shares) at Jun. 30, 2023 | 74,143 | ||||
Beginning balance at Mar. 31, 2023 | 395,183 | $ 7 | 1,003,949 | (5,896) | (602,877) |
Beginning balance (in shares) at Mar. 31, 2023 | 68,439 | ||||
Share-based compensation expense | 6,987 | 6,987 | |||
Issuance of common stock under equity plans | 431 | 431 | |||
Issuance of common stock under equity plans, shares | 43 | ||||
Issuance of common stock, net of offering costs, (in shares) | 5,661 | ||||
Issuance of common stock, net of offering costs | 60,919 | 60,919 | |||
Issuance of pre-funded warrants to purchase common stock, net of offering costs | 32,658 | 32,658 | |||
Other comprehensive income (loss) | 674 | 674 | |||
Net loss | (37,174) | (37,174) | |||
Ending balance at Jun. 30, 2023 | $ 459,678 | $ 7 | $ 1,104,944 | $ (5,222) | $ (640,051) |
Ending balance (in shares) at Jun. 30, 2023 | 74,143 |
Condensed Statements of Cash Fl
Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2023 | Jun. 30, 2022 | |
Operating Activities | ||
Net loss | $ (71,243) | $ (67,222) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Share-based compensation expense | 13,825 | 13,158 |
Amortization of premium and accretion of discounts on marketable securities, net | (3,797) | 1,894 |
Depreciation expense | 419 | 360 |
Non-cash interest expense | 236 | |
Changes in operating assets and liabilities: | ||
Prepaid expenses and other current assets | (226) | (5,199) |
Operating lease right-of-use and other long-term assets | 502 | (5) |
Accounts payable and accrued expenses | (1,251) | (5,592) |
Other long-term liabilities | 46 | 84 |
Net cash used in operating activities | (61,489) | (62,522) |
Investing Activities | ||
Purchases of marketable securities | (213,464) | (107,579) |
Maturities of marketable securities | 178,399 | 115,947 |
Purchases of property and equipment | (132) | (233) |
Net cash (used in) provided by investing activities | (35,197) | 8,135 |
Financing Activities | ||
Proceeds from issuance of common stock and pre-funded warrants, net of offering costs | 93,577 | |
Proceeds from issuance of stock under equity plans | 431 | 2,972 |
Net cash provided by financing activities | 94,008 | 2,972 |
Net decrease in cash, cash equivalents and restricted cash | (2,678) | (51,415) |
Cash, cash equivalents and restricted cash at beginning of period | 52,012 | 90,882 |
Cash, cash equivalents and restricted cash at end of period | $ 49,334 | $ 39,467 |
Organization and Basis of Prese
Organization and Basis of Presentation | 6 Months Ended |
Jun. 30, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Basis of Presentation | 1. Organization and Basis of Presentation The Company Kura Oncology, Inc. is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule product candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes, and we intend to pair them with molecular or cellular diagnostics to identify those patients most likely to respond to treatment. We plan to advance our product candidates through a combination of internal development and strategic partnerships while maintaining significant development and commercial rights. References in these Notes to Unaudited Condensed Financial Statements to the “Company,” “we,” “our” or “us,” refer to Kura Oncology, Inc. Basis of Presentation The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission on February 23, 2023, from which we derived our balance sheet as of December 31, 2022. The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying unaudited condensed financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying unaudited condensed financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year. The preparation of the unaudited condensed financial statements in accordance with GAAP requires our management to make estimates and assumptions that affect the amounts reported on our unaudited condensed financial statements and accompanying notes. The amounts reported could differ under different estimates and assumptions. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2023 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies Restricted Cash Under the terms of an office lease entered into in March 2020, we are required to maintain a standby letter of credit during the term of the lease. As of June 30, 2023 , restricted cash of $ 0.2 million was pledged as collateral for the letter of credit. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the unaudited condensed balance sheets that sum to the total of the amounts shown in the unaudited condensed statements of cash flows, in thousands: June 30, 2023 December 31, 2022 June 30, 2022 December 31, 2021 Cash and cash equivalents $ 49,124 $ 51,802 $ 39,257 $ 90,672 Restricted cash 210 210 210 210 Total $ 49,334 $ 52,012 $ 39,467 $ 90,882 Allowance for Credit Losses For available-for-sale securities in an unrealized loss position, we first assess whether we intend to sell, or if it is more likely than not that we will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through earnings. For available-for-sale securities that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the severity of the impairment, any changes in interest rates, market conditions, changes to the underlying credit ratings and forecasted recovery, among other factors. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income through an allowance account. Any impairment that has not been recorded through an allowance for credit losses is included in other comprehensive income (loss) on the unaudited condensed statements of operations and comprehensive loss. We elected the practical expedient to exclude the applicable accrued interest from both the fair value and amortized costs basis of our available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable on available-for-sale securities is recorded within prepaid expenses and other current assets on our unaudited condensed balance sheets. Our accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which we consider to be in the period in which we determine the accrued interest will not be collected by us. Concentration of Credit Risk Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. We maintain deposits in federally insured financial institutions in excess of federally insured limits. We have established guidelines to limit our exposure to credit risk by placing investments with high credit quality financial institutions, diversifying our investment portfolio and placing investments with maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity. Employee Retention Credit Under the Coronavirus Aid, Relief, and Economic Security Act of 2020, or CARES Act, we were eligible to claim the employee retention credit, which is a refundable tax credit against certain employment taxes. For the six months ended June 30, 2023 , we recognized $ 2.8 million of employee retention credits related to wages paid to our employees from July 2020 through September 2021 within operating expenses as a reduction to personnel costs in the unaudited condensed statements of operations and comprehensive loss. We file d for the credit with the Internal Revenue Service in the first quarter of 2023. As of June 30, 2023 , an employee retention credit receivable of $ 2.8 million w as included within prepaid expenses and other current assets in the unaudited condensed balance sheets and we expect to receive such credit in the form of a cash payment during the second half of 2023. Net Loss per Share Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, which includes the shares related to outstanding pre-funded warrants (see Note 7), but excludes other potential common stock equivalents. Pre-funded warrants are considered outstanding for the purposes of computing basic and diluted net loss per share because shares may be issued for little or no additional consideration, and are fully vested and exercisable. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares and common stock equivalents outstanding for the period. As we have reported net loss for the three and six months ended June 30, 2023 and 2022, dilutive net loss per common share is the same as basic net loss per common share for those periods. Common stock equivalents outstanding are comprised of stock options, restricted stock units, performance-based restricted stock units, warrants and employee stock purchase plan rights and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. Common stock equivalents outstanding at June 30, 2023 and 2022 totaling approxim ately 13,743,000 and 9,101,000 , respectively, were excluded from the computation of dilutive weighted-average shares outstanding because their effect would be anti-dilutive. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that we adopt as of the specified effective date. We have evaluated recently issued accounting pronouncements and, based on our preliminary assessment, we do not believe any will have a material impact on our unaudited condensed financial statements or related footnote disclosures. |
Investments
Investments | 6 Months Ended |
Jun. 30, 2023 | |
Investments, All Other Investments [Abstract] | |
Investments | 3. Investments We invest in available-for-sale securities consisting of money market funds, U.S. Treasury securities, corporate debt securities, commercial paper, U.S. Agency bonds and non-U.S. government and supranational debt securities. Available-for-sale securities are classified as either cash and cash equivalents or short-term investments on our unaudited condensed balance sheets. The following tables summarize, by major security type, our short-term investments that are measured at fair value on a recurring basis, in thousands: June 30, 2023 Maturities Amortized Unrealized Unrealized Fair Value Cash equivalents: Money market funds 1 or less $ 38,460 $ — $ — $ 38,460 Short-term investments: U.S. Treasury securities 2 or less 244,260 5 ( 2,035 ) 242,230 Corporate debt securities 2 or less 92,723 — ( 2,509 ) 90,214 Commercial paper 1 or less 55,780 — ( 45 ) 55,735 U.S. Agency bonds 1 or less 22,060 17 ( 15 ) 22,062 Non-U.S. government and supranational debt securities 1 or less 18,254 — ( 640 ) 17,614 Total short-term investments 433,077 22 ( 5,244 ) 427,855 Total $ 471,537 $ 22 $ ( 5,244 ) $ 466,315 December 31, 2022 Maturities Amortized Unrealized Unrealized Fair Value Cash equivalents: Money market funds 1 or less $ 37,878 $ — $ — $ 37,878 U.S. Agency bonds 1 or less 9,956 — — 9,956 Total cash equivalents 47,834 — — 47,834 Short-term investments: U.S. Treasury securities 2 or less 183,051 16 ( 3,018 ) 180,049 Corporate debt securities 2 or less 115,763 — ( 3,931 ) 111,832 Commercial paper 1 or less 52,941 — — 52,941 U.S. Agency bonds 1 or less 16,192 11 ( 160 ) 16,043 Non-U.S. government and supranational debt securities 2 or less 26,268 — ( 950 ) 25,318 Total short-term investments 394,215 27 ( 8,059 ) 386,183 Total $ 442,049 $ 27 $ ( 8,059 ) $ 434,017 Short-term investments are classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date, which reflects management’s intention to use the proceeds from sales of these securities to fund our operations, as necessary. As of June 30, 2023 and December 31, 2022 , short-term investments of $ 368.5 million and $ 274.3 million, respectively, had maturities less than one year, and short-term investments of $ 59.4 million and $ 111.9 million, respectively, had maturities between one to two years. We had no realized gains or losses for the six months ended June 30, 2023 and 2022. As of June 30, 2023, 52 av ailable-for-sale securities with a fair market value of $ 387.4 million w ere in gross unrealized loss po sitions, $ 144.0 million of wh ich were in a continuous unrealized loss position for greater than 12 months. We do not intend to sell these available-for-sale securities, and it is not more likely than not that we will be required to sell these securities prior to recovery of their amortized cost basis. Based on our review of these available-for-sale securities, the unrealized losses at June 30, 2023 were primarily due to changes in interest rates and not due to increased credit risks associated with specific securities. W e have no allowance for credit losses as of June 30, 2023 and December 31, 2022. Unrealized gains and losses that are not credit-related are included in accumulated other comprehensive loss. Accrued interest receivable on available-for-sale securities was $ 0.9 million as of June 30, 2023 and December 31, 2022. We have not written off any accrued interest receivables for the six months ended June 30, 2023 and 2022 . |
Fair Value Measurements
Fair Value Measurements | 6 Months Ended |
Jun. 30, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | 4. Fair Value Measurements As of June 30, 2023 and December 31, 2022, we had cash equivalents and short-term investments measured at fair value on a recurring basis. Available-for-sale securities consist of U.S. Treasury securities, which are measured at fair value using Level 1 inputs, and corporate debt securities, commercial paper, U.S. Agency bonds and non-U.S. government and supranational debt securities which are measured at fair value using Level 2 inputs. We determine the fair value of Level 2 related securities with the aid of valuations provided by third parties using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. We validate the fair values of Level 2 financial instruments by comparing these fair values to a third-party pricing source. The following tables summarize, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy, in thousands: June 30, 2023 Total Level 1 Level 2 Cash equivalents: Money market funds $ 38,460 $ 38,460 $ — Short-term investments: U.S. Treasury securities 242,230 242,230 — Corporate debt securities 90,214 — 90,214 Commercial paper 55,735 — 55,735 U.S. Agency bonds 22,062 — 22,062 Non-U.S. government and supranational debt securities 17,614 — 17,614 Total short-term investments 427,855 242,230 185,625 Total $ 466,315 $ 280,690 $ 185,625 December 31, 2022 Total Level 1 Level 2 Cash equivalents: Money market funds $ 37,878 $ 37,878 $ — U.S. Agency bonds 9,956 — 9,956 Total cash equivalents 47,834 37,878 9,956 Short-term investments: U.S. Treasury securities 180,049 180,049 — Corporate debt securities 111,832 — 111,832 Commercial paper 52,941 — 52,941 U.S. Agency bonds 16,043 — 16,043 Non-U.S. government and supranational debt securities 25,318 — 25,318 Total short-term investments 386,183 180,049 206,134 Total $ 434,017 $ 217,927 $ 216,090 We believe that our term loan facility bears interest at a rate that approximates prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value of the term loan facility approximates fair value. The fair value of our term loan facility is determined using Level 2 inputs in the fair value hierarchy. |
Balance Sheet Detail
Balance Sheet Detail | 6 Months Ended |
Jun. 30, 2023 | |
Balance Sheet Related Disclosures [Abstract] | |
Balance Sheet Detail | 5. Balance Sheet Detail Property and equipment consisted of the following, in thousands: June 30, 2023 December 31, 2022 Laboratory and computer equipment $ 1,637 $ 1,568 Leasehold improvements 1,543 1,543 Furniture and fixtures 1,095 1,032 Property and equipment, gross 4,275 4,143 Less: accumulated depreciation ( 2,022 ) ( 1,603 ) Property and equipment, net $ 2,253 $ 2,540 Accounts payable and accrued expenses consisted of the following, in thousands: June 30, 2023 December 31, 2022 Accounts payable $ 2,337 $ 1,533 Accrued clinical trial research and development expenses 3,857 2,440 Accrued other research and development expenses 6,781 5,030 Accrued compensation and benefits 6,840 10,300 Other accrued expenses 1,739 2,436 Total accounts payable and accrued expenses $ 21,554 $ 21,739 |
Leases
Leases | 6 Months Ended |
Jun. 30, 2023 | |
Leases [Abstract] | |
Leases | 6. Leases We currently have three operating leases for administrative and research and development office and lab space in San Diego, California and Boston, Massachusetts that expire between July 2024 and November 2025. Under the terms of the operating leases, we are required to pay our proportionate share of property taxes, insurance and normal maintenance costs. Two of our leases include renewal options for an additional five years , which were not included in the determination of the right-of-use, or ROU, asset or lease liability as the renewal was not reasonably certain at the inception of the lease . Our San Diego corporate headquarters lease and our San Diego lease for lab and office space provided for $ 1.0 million and $ 0.1 million, respectively, in reimbursements for allowable tenant improvements, which effectively reduced the total lease payments owed. Under the terms of our office lease in Boston, we are required to maintain a standby letter of credit of approximately $ 0.2 million during the term of the lease. Maturities of lease liabilities as of June 30, 2023 are as follows, in thousands: Year Ending December 31, 2023 (remaining) $ 1,196 2024 1,863 2025 929 Total lease payments 3,988 Less: imputed interest ( 188 ) Total operating lease liabilities $ 3,800 As of June 30, 2023 and December 31, 2022, the weighted-average discoun t rate was 5.5 % f or both periods, and the weighted-average remaining lease ter m was 1.9 years and 2.3 years, respectively. Total cash paid for amounts included in the measurement of operating lease lia bilities was $ 0.6 million for both the three months ended June 30, 2023 and 2022. Total cash paid for amounts included in the measurement of operating lease lia bilities was $ 1.2 million for both the six months ended June 30, 2023 and 2022 . There were no operating lease ROU assets obtained in exchange for operating lease liabilities for the six months ended June 30, 2023 and 2022. Total operating lease expense for the three months ended June 30, 2023 and 2022 was approximately $ 0.5 million in both periods. Total operating lease expense for the six months ended June 30, 2023 and 2022 was approximately $ 1.0 million in both periods. |
Stockholders' Equity
Stockholders' Equity | 6 Months Ended |
Jun. 30, 2023 | |
Equity [Abstract] | |
Stockholders' Equity | 7. Stockholders’ Equity In June 2023, we completed a public offering in which we sold an aggregate of 5,660,871 shares of our common stock at a price of $ 11.50 per share and pre-funded warrants to purchase 3,034,782 shares of our common stock at a price of $ 11.4999 per pre-funded warrant. The exercise price of each pre-funded warrant is $ 0.0001 per share and the pre-funded warrants are exercisable from the date of issuance until fully exercised. Net proceeds from the public offering, after deducting underwriting discounts and commissions and offering expenses, were approximately $ 93.6 million. In addition, the underwriters were granted a 30-day option to purchase up to 1,304,347 additional shares of our common stock, or the Overallotment Option, at the $ 11.50 per share public offering price. The common stock, pre-funded warrants, and Overallotment Option met the accounting standards guidance for equity classification. As of June 30, 2023 the Overallotment Option was unexercised and it subsequently expired without being exercised in July 2023. We measured the fair value of the Overallotment Option using the Black-Scholes valuation model, which represents a Level 3 fair value measurement, and determined that the value was not material. |
Share-Based Compensation
Share-Based Compensation | 6 Months Ended |
Jun. 30, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Share-Based Compensation | Share-Based Compensation Equity Incentive Plan In May 2023, our stockholders approved an amendment to our Amended and Restated 2014 Equity Incentive Plan, or 2014 Plan, to, among other things, increase the number of shares available for future grant by 4,050,000 shares and remove the automatic annual 4 % increase to the number of shares available for future grant. Performance-Based Restricted Stock Units On May 31, 2023, upon approval by our stockholders of our amended 2014 Plan, we granted an aggregate of 1,313,100 performance-based restricted stock units, or PSUs, to certain executives. The PSUs vest in six equal tranches upon the achievement of certain milestones and service conditions. Share-Based Compensation Expense The following table summarizes share-based compensation expense for all share-based compensation arrangements, in thousands: Three Months Ended Six Months Ended June 30, June 30, 2023 2022 2023 2022 Research and development $ 3,134 $ 2,597 $ 6,207 $ 5,053 General and administrative 3,853 3,911 7,618 8,105 Total share-based compensation expense $ 6,987 $ 6,508 $ 13,825 $ 13,158 As of June 30, 2023, unrecognized estimated compensation expense related to stock options and restricted stock units was approximate ly $ 45.4 million and $ 12.6 million, resp ectively, which is expected to be recognized over a weighted average period of approxim ately 2.6 years f or both stock options and restricted stock units. As of June 30, 2023, we determined that the vesting of the PSUs was not probable and therefore have not included them in share-based compensation expense or unrecognized estimated compensation expense. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2023 | |
Accounting Policies [Abstract] | |
Restricted Cash | Restricted Cash Under the terms of an office lease entered into in March 2020, we are required to maintain a standby letter of credit during the term of the lease. As of June 30, 2023 , restricted cash of $ 0.2 million was pledged as collateral for the letter of credit. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the unaudited condensed balance sheets that sum to the total of the amounts shown in the unaudited condensed statements of cash flows, in thousands: June 30, 2023 December 31, 2022 June 30, 2022 December 31, 2021 Cash and cash equivalents $ 49,124 $ 51,802 $ 39,257 $ 90,672 Restricted cash 210 210 210 210 Total $ 49,334 $ 52,012 $ 39,467 $ 90,882 |
Allowance for Credit Losses on Available-for-Sale Debt Securities | Allowance for Credit Losses For available-for-sale securities in an unrealized loss position, we first assess whether we intend to sell, or if it is more likely than not that we will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through earnings. For available-for-sale securities that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the severity of the impairment, any changes in interest rates, market conditions, changes to the underlying credit ratings and forecasted recovery, among other factors. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income through an allowance account. Any impairment that has not been recorded through an allowance for credit losses is included in other comprehensive income (loss) on the unaudited condensed statements of operations and comprehensive loss. We elected the practical expedient to exclude the applicable accrued interest from both the fair value and amortized costs basis of our available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable on available-for-sale securities is recorded within prepaid expenses and other current assets on our unaudited condensed balance sheets. Our accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which we consider to be in the period in which we determine the accrued interest will not be collected by us. |
Concentration of Credit Risk | Concentration of Credit Risk Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. We maintain deposits in federally insured financial institutions in excess of federally insured limits. We have established guidelines to limit our exposure to credit risk by placing investments with high credit quality financial institutions, diversifying our investment portfolio and placing investments with maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity. |
Net Loss per Share | Net Loss per Share Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, which includes the shares related to outstanding pre-funded warrants (see Note 7), but excludes other potential common stock equivalents. Pre-funded warrants are considered outstanding for the purposes of computing basic and diluted net loss per share because shares may be issued for little or no additional consideration, and are fully vested and exercisable. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares and common stock equivalents outstanding for the period. As we have reported net loss for the three and six months ended June 30, 2023 and 2022, dilutive net loss per common share is the same as basic net loss per common share for those periods. Common stock equivalents outstanding are comprised of stock options, restricted stock units, performance-based restricted stock units, warrants and employee stock purchase plan rights and are only included in the calculation of diluted earnings per common share when net income is reported and their effect is dilutive. Common stock equivalents outstanding at June 30, 2023 and 2022 totaling approxim ately 13,743,000 and 9,101,000 , respectively, were excluded from the computation of dilutive weighted-average shares outstanding because their effect would be anti-dilutive. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that we adopt as of the specified effective date. We have evaluated recently issued accounting pronouncements and, based on our preliminary assessment, we do not believe any will have a material impact on our unaudited condensed financial statements or related footnote disclosures. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Accounting Policies [Abstract] | |
Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash | The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the unaudited condensed balance sheets that sum to the total of the amounts shown in the unaudited condensed statements of cash flows, in thousands: June 30, 2023 December 31, 2022 June 30, 2022 December 31, 2021 Cash and cash equivalents $ 49,124 $ 51,802 $ 39,257 $ 90,672 Restricted cash 210 210 210 210 Total $ 49,334 $ 52,012 $ 39,467 $ 90,882 |
Investments (Tables)
Investments (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Investments, All Other Investments [Abstract] | |
Investments Measured at Fair Value on Recurring Basis | The following tables summarize, by major security type, our short-term investments that are measured at fair value on a recurring basis, in thousands: June 30, 2023 Maturities Amortized Unrealized Unrealized Fair Value Cash equivalents: Money market funds 1 or less $ 38,460 $ — $ — $ 38,460 Short-term investments: U.S. Treasury securities 2 or less 244,260 5 ( 2,035 ) 242,230 Corporate debt securities 2 or less 92,723 — ( 2,509 ) 90,214 Commercial paper 1 or less 55,780 — ( 45 ) 55,735 U.S. Agency bonds 1 or less 22,060 17 ( 15 ) 22,062 Non-U.S. government and supranational debt securities 1 or less 18,254 — ( 640 ) 17,614 Total short-term investments 433,077 22 ( 5,244 ) 427,855 Total $ 471,537 $ 22 $ ( 5,244 ) $ 466,315 December 31, 2022 Maturities Amortized Unrealized Unrealized Fair Value Cash equivalents: Money market funds 1 or less $ 37,878 $ — $ — $ 37,878 U.S. Agency bonds 1 or less 9,956 — — 9,956 Total cash equivalents 47,834 — — 47,834 Short-term investments: U.S. Treasury securities 2 or less 183,051 16 ( 3,018 ) 180,049 Corporate debt securities 2 or less 115,763 — ( 3,931 ) 111,832 Commercial paper 1 or less 52,941 — — 52,941 U.S. Agency bonds 1 or less 16,192 11 ( 160 ) 16,043 Non-U.S. government and supranational debt securities 2 or less 26,268 — ( 950 ) 25,318 Total short-term investments 394,215 27 ( 8,059 ) 386,183 Total $ 442,049 $ 27 $ ( 8,059 ) $ 434,017 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Fair Value Disclosures [Abstract] | |
Schedule Of Fair Value Measurements, By Major Security Type | The following tables summarize, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy, in thousands: June 30, 2023 Total Level 1 Level 2 Cash equivalents: Money market funds $ 38,460 $ 38,460 $ — Short-term investments: U.S. Treasury securities 242,230 242,230 — Corporate debt securities 90,214 — 90,214 Commercial paper 55,735 — 55,735 U.S. Agency bonds 22,062 — 22,062 Non-U.S. government and supranational debt securities 17,614 — 17,614 Total short-term investments 427,855 242,230 185,625 Total $ 466,315 $ 280,690 $ 185,625 December 31, 2022 Total Level 1 Level 2 Cash equivalents: Money market funds $ 37,878 $ 37,878 $ — U.S. Agency bonds 9,956 — 9,956 Total cash equivalents 47,834 37,878 9,956 Short-term investments: U.S. Treasury securities 180,049 180,049 — Corporate debt securities 111,832 — 111,832 Commercial paper 52,941 — 52,941 U.S. Agency bonds 16,043 — 16,043 Non-U.S. government and supranational debt securities 25,318 — 25,318 Total short-term investments 386,183 180,049 206,134 Total $ 434,017 $ 217,927 $ 216,090 |
Balance Sheet Detail (Tables)
Balance Sheet Detail (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Balance Sheet Related Disclosures [Abstract] | |
Summary of Property and Equipment | Property and equipment consisted of the following, in thousands: June 30, 2023 December 31, 2022 Laboratory and computer equipment $ 1,637 $ 1,568 Leasehold improvements 1,543 1,543 Furniture and fixtures 1,095 1,032 Property and equipment, gross 4,275 4,143 Less: accumulated depreciation ( 2,022 ) ( 1,603 ) Property and equipment, net $ 2,253 $ 2,540 |
Summary of Accounts Payable and Accrued Expenses | Accounts payable and accrued expenses consisted of the following, in thousands: June 30, 2023 December 31, 2022 Accounts payable $ 2,337 $ 1,533 Accrued clinical trial research and development expenses 3,857 2,440 Accrued other research and development expenses 6,781 5,030 Accrued compensation and benefits 6,840 10,300 Other accrued expenses 1,739 2,436 Total accounts payable and accrued expenses $ 21,554 $ 21,739 |
Leases (Tables)
Leases (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Leases [Abstract] | |
Schedule of Maturities of Lease Liabilities | Maturities of lease liabilities as of June 30, 2023 are as follows, in thousands: Year Ending December 31, 2023 (remaining) $ 1,196 2024 1,863 2025 929 Total lease payments 3,988 Less: imputed interest ( 188 ) Total operating lease liabilities $ 3,800 |
Share-Based Compensation (Table
Share-Based Compensation (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Summary of Share-based Compensation Expense | The following table summarizes share-based compensation expense for all share-based compensation arrangements, in thousands: Three Months Ended Six Months Ended June 30, June 30, 2023 2022 2023 2022 Research and development $ 3,134 $ 2,597 $ 6,207 $ 5,053 General and administrative 3,853 3,911 7,618 8,105 Total share-based compensation expense $ 6,987 $ 6,508 $ 13,825 $ 13,158 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands | 6 Months Ended | |||
Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | |
Summary Of Significant Accounting Policies [Line Items] | ||||
Restricted cash pledged as collateral | $ 210 | $ 210 | $ 210 | $ 210 |
Employee retention credit recognized during period | 2,800 | |||
Employee retention credit receivable during period | $ 2,800 | |||
Total potentially dilutive securities | 13,743,000 | 9,101,000 | ||
Collateral Pledged | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Restricted cash pledged as collateral | $ 200 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 | Jun. 30, 2022 | Dec. 31, 2021 |
Accounting Policies [Abstract] | ||||
Cash and cash equivalents | $ 49,124 | $ 51,802 | $ 39,257 | $ 90,672 |
Restricted cash | 210 | 210 | 210 | 210 |
Total | $ 49,334 | $ 52,012 | $ 39,467 | $ 90,882 |
Investments - Investments Measu
Investments - Investments Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Schedule Of Available For Sale Securities [Line Items] | ||
Short-term investments, Fair Value | $ 427,855 | $ 386,183 |
Fair Value Measurements on Recurring Basis | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Cash equivalents, Amortized Cost | 47,834 | |
Cash equivalents, Fair Value | 47,834 | |
Short-term investments, Amortized Cost | 433,077 | 394,215 |
Short-term investments, Unrealized Gains | 22 | 27 |
Short-term investments, Unrealized Losses | (5,244) | (8,059) |
Short-term investments, Fair Value | 427,855 | 386,183 |
Cash equivalents and Short-term investments, Amortized Cost | 471,537 | 442,049 |
Cash equivalents and Short-term investments, Unrealized Gains | 22 | 27 |
Cash equivalents and Short-term investments, Unrealized Losses | (5,244) | (8,059) |
Cash equivalents and Short-term investments, Estimated Fair Value | 466,315 | 434,017 |
Fair Value Measurements on Recurring Basis | Money Market Funds | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Cash equivalents, Amortized Cost | 38,460 | 37,878 |
Cash equivalents, Fair Value | $ 38,460 | $ 37,878 |
Fair Value Measurements on Recurring Basis | Money Market Funds | Maximum | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Maturities (years) | 1 year | 1 year |
Fair Value Measurements on Recurring Basis | U.S. Treasury Securities | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Short-term investments, Amortized Cost | $ 244,260 | $ 183,051 |
Short-term investments, Unrealized Gains | 5 | 16 |
Short-term investments, Unrealized Losses | (2,035) | (3,018) |
Short-term investments, Fair Value | $ 242,230 | $ 180,049 |
Fair Value Measurements on Recurring Basis | U.S. Treasury Securities | Maximum | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Maturities (years) | 2 years | 2 years |
Fair Value Measurements on Recurring Basis | Corporate Debt Securities | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Short-term investments, Amortized Cost | $ 92,723 | $ 115,763 |
Short-term investments, Unrealized Losses | (2,509) | (3,931) |
Short-term investments, Fair Value | $ 90,214 | $ 111,832 |
Fair Value Measurements on Recurring Basis | Corporate Debt Securities | Maximum | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Maturities (years) | 2 years | 2 years |
Fair Value Measurements on Recurring Basis | Commercial Paper | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Short-term investments, Amortized Cost | $ 55,780 | $ 52,941 |
Short-term investments, Unrealized Losses | (45) | |
Short-term investments, Fair Value | $ 55,735 | $ 52,941 |
Fair Value Measurements on Recurring Basis | Commercial Paper | Maximum | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Maturities (years) | 1 year | 1 year |
Fair Value Measurements on Recurring Basis | U.S. Agency Bonds | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Cash equivalents, Amortized Cost | $ 9,956 | |
Cash equivalents, Fair Value | 9,956 | |
Short-term investments, Amortized Cost | $ 22,060 | 16,192 |
Short-term investments, Unrealized Gains | 17 | 11 |
Short-term investments, Unrealized Losses | (15) | (160) |
Short-term investments, Fair Value | $ 22,062 | $ 16,043 |
Fair Value Measurements on Recurring Basis | U.S. Agency Bonds | Maximum | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Maturities (years) | 1 year | |
Maturities (years) | 1 year | 1 year |
Fair Value Measurements on Recurring Basis | Non U S Government And Supranational Debt Securities | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Short-term investments, Amortized Cost | $ 18,254 | $ 26,268 |
Short-term investments, Unrealized Losses | (640) | (950) |
Short-term investments, Fair Value | $ 17,614 | $ 25,318 |
Fair Value Measurements on Recurring Basis | Non U S Government And Supranational Debt Securities | Maximum | ||
Schedule Of Available For Sale Securities [Line Items] | ||
Maturities (years) | 1 year | 2 years |
Investments - Additional Inform
Investments - Additional Information (Detail) $ in Thousands | 6 Months Ended | |
Jun. 30, 2023 USD ($) Security | Dec. 31, 2022 USD ($) | |
Investments, All Other Investments [Abstract] | ||
Short-term investments with maturities less than one year | $ 368,500 | $ 274,300 |
Short-term investments with maturities between one and two years | $ 59,400 | 111,900 |
Short-term investments maturities, description | As of June 30, 2023 and December 31, 2022, short-term investments of $368.5 million and $274.3 million, respectively, had maturities less than one year, and short-term investments of $59.4 million and $111.9 million, respectively, had maturities between one to two years. | |
Allowance for credit losses | $ 0 | 0 |
Available for sale securities gross unrealized loss positions | 387,400 | |
Available for sale securities gross unrealized loss positions greater than 12 months | $ 144,000 | |
Number of available-for-sale securities | Security | 52 | |
Accrued interest receivable on available-for-sale securities | $ 900 | $ 900 |
Fair Value Measurements - Sched
Fair Value Measurements - Schedule Of Fair Value Measurements, By Major Security Type (Detail) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Short-term investments | $ 427,855 | $ 386,183 |
Fair Value Measurements on Recurring Basis | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Cash equivalents | 47,834 | |
Short-term investments | 427,855 | 386,183 |
Cash equivalents and short-term investments | 466,315 | 434,017 |
Fair Value Measurements on Recurring Basis | Level 1 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Cash equivalents | 37,878 | |
Short-term investments | 242,230 | 180,049 |
Cash equivalents and short-term investments | 280,690 | 217,927 |
Fair Value Measurements on Recurring Basis | Level 2 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Cash equivalents | 9,956 | |
Short-term investments | 185,625 | 206,134 |
Cash equivalents and short-term investments | 185,625 | 216,090 |
Fair Value Measurements on Recurring Basis | Money Market Funds | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Cash equivalents | 38,460 | 37,878 |
Fair Value Measurements on Recurring Basis | Money Market Funds | Level 1 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Cash equivalents | 38,460 | 37,878 |
Fair Value Measurements on Recurring Basis | U.S. Treasury Securities | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Short-term investments | 242,230 | 180,049 |
Fair Value Measurements on Recurring Basis | U.S. Treasury Securities | Level 1 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Short-term investments | 242,230 | 180,049 |
Fair Value Measurements on Recurring Basis | Corporate Debt Securities | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Short-term investments | 90,214 | 111,832 |
Fair Value Measurements on Recurring Basis | Corporate Debt Securities | Level 2 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Short-term investments | 90,214 | 111,832 |
Fair Value Measurements on Recurring Basis | Commercial Paper | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Short-term investments | 55,735 | 52,941 |
Fair Value Measurements on Recurring Basis | Commercial Paper | Level 2 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Short-term investments | 55,735 | 52,941 |
Fair Value Measurements on Recurring Basis | U S Agency Bonds | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Cash equivalents | 9,956 | |
Short-term investments | 22,062 | 16,043 |
Fair Value Measurements on Recurring Basis | U S Agency Bonds | Level 2 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Cash equivalents | 9,956 | |
Short-term investments | 22,062 | 16,043 |
Fair Value Measurements on Recurring Basis | Non U S Government And Supranational Debt Securities | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Short-term investments | 17,614 | 25,318 |
Fair Value Measurements on Recurring Basis | Non U S Government And Supranational Debt Securities | Level 2 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Short-term investments | $ 17,614 | $ 25,318 |
Balance Sheet Detail - Summary
Balance Sheet Detail - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | $ 4,275 | $ 4,143 |
Less: accumulated depreciation | (2,022) | (1,603) |
Property and equipment, net | 2,253 | 2,540 |
Laboratory and Computer Equipment | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | 1,637 | 1,568 |
Leasehold Improvements | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | 1,543 | 1,543 |
Furniture and Fixtures | ||
Property Plant And Equipment [Line Items] | ||
Property and equipment, gross | $ 1,095 | $ 1,032 |
Balance Sheet Detail - Summar_2
Balance Sheet Detail - Summary of Current Accrued Expenses (Detail) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Accrued Liabilities, Current [Abstract] | ||
Accounts payable | $ 2,337 | $ 1,533 |
Accrued clinical trial research and development expenses | 3,857 | 2,440 |
Accrued other research and development expenses | 6,781 | 5,030 |
Accrued compensation and benefits | 6,840 | 10,300 |
Other accrued expenses | 1,739 | 2,436 |
Total accounts payable and accrued expenses | $ 21,554 | $ 21,739 |
Leases - Additional Information
Leases - Additional Information (Detail) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | |||||
May 31, 2020 | Mar. 31, 2020 | Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | May 31, 2022 | |
Lessee Lease Description [Line Items] | ||||||||
Lessee, operating lease, expiration period | We currently have three operating leases for administrative and research and development office and lab space in San Diego, California and Boston, Massachusetts that expire between July 2024 and November 2025. | |||||||
Lease option to extend, description | Two of our leases include renewal options for an additional five years, which were not included in the determination of the right-of-use, or ROU, asset or lease liability as the renewal was not reasonably certain at the inception of the lease | |||||||
Weighted-average discount rate | 5.50% | 5.50% | 5.50% | |||||
Weighted-average remaining lease term | 1 year 10 months 24 days | 1 year 10 months 24 days | 2 years 3 months 18 days | |||||
Total cash paid for amounts included in the measurement of lease liabilities | $ 600,000 | $ 600,000 | $ 1,200,000 | $ 1,200,000 | ||||
ROU assets obtained in exchange for operating lease liabilities | 0 | 0 | ||||||
ASC 842 | ||||||||
Lessee Lease Description [Line Items] | ||||||||
Total operating lease rent expense | 500,000 | $ 500,000 | 1,000,000 | $ 1,000,000 | ||||
San Diego Corporate Headquarters Lease | ||||||||
Lessee Lease Description [Line Items] | ||||||||
Operating lease, existence of option to extend | true | |||||||
Lease agreement additional extended lease term | 5 years | |||||||
Tenant improvement allowance | $ 1,000,000 | |||||||
San Diego Lease for Lab and Office Space | ||||||||
Lessee Lease Description [Line Items] | ||||||||
Tenant improvement allowance | $ 100,000 | |||||||
Office Lease in Boston | Letter of Credit | ||||||||
Lessee Lease Description [Line Items] | ||||||||
Letter of Credit | $ 200,000 | $ 200,000 | ||||||
Boston Lease | ||||||||
Lessee Lease Description [Line Items] | ||||||||
Operating lease, existence of option to extend | true | |||||||
Lease agreement additional extended lease term | 5 years |
Leases - Schedule of Maturities
Leases - Schedule of Maturities of Lease Liabilities (Detail) $ in Thousands | Jun. 30, 2023 USD ($) |
Leases [Abstract] | |
2023 (remaining) | $ 1,196 |
2024 | 1,863 |
2025 | 929 |
Total lease payments | 3,988 |
Less: imputed interest | (188) |
Total operating lease liabilities | $ 3,800 |
Stockholder's Equity - Addition
Stockholder's Equity - Additional Information (Detail) $ / shares in Units, $ in Thousands | 1 Months Ended | 6 Months Ended |
Jun. 30, 2023 USD ($) $ / shares shares | Jun. 30, 2023 USD ($) $ / shares | |
Class of Stock [Line Items] | ||
Common stock, shares issued | shares | 5,660,871 | |
Common stock, issued price per share | $ 11.5 | $ 11.5 |
Proceeds from issuance of common stock and pre-funded warrants, net of offering costs | $ | $ 93,600 | $ 93,577 |
Pre-funded Warrants | ||
Class of Stock [Line Items] | ||
Warrants issued | shares | 3,034,782 | |
Warrants issued price per warrants | $ 11.4999 | $ 11.4999 |
Warrants exercisable exercise price | 0.0001 | 0.0001 |
Overallotment Option | ||
Class of Stock [Line Items] | ||
Common stock, issued price per share | $ 11.5 | $ 11.5 |
Option to purchase additional shares of common stock | shares | 1,304,347 |
Share-Based Compensation - Addi
Share-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions | 6 Months Ended | 12 Months Ended | |
May 31, 2023 | Jun. 30, 2023 | Dec. 31, 2022 | |
Amended and Restated 2014 Equity Incentive Plan | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Percentage of automatic increase in common shares reserved for future issuance pursuant to future grants | 4% | ||
Additional shares available for future grant | 4,050,000 | ||
Employee Stock Option | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Unrecognized estimated stock option compensation expenses | $ 45.4 | ||
Weighted average service period | 2 years 7 months 6 days | ||
Restricted Stock Units | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
Unrecognized estimated restricted stock units compensation expenses | $ 12.6 | ||
Weighted average service period | 2 years 7 months 6 days | ||
Performance Based Restricted Stock Units | Amended and Restated 2014 Equity Incentive Plan | |||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||
PSUs Granted | 1,313,100 |
Share-Based Compensation - Summ
Share-Based Compensation - Summary of Share-based Compensation Expense (Detail) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Share-based compensation expense | $ 6,987 | $ 6,508 | $ 13,825 | $ 13,158 |
Research and development | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Share-based compensation expense | 3,134 | 2,597 | 6,207 | 5,053 |
General and administrative | ||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||
Share-based compensation expense | $ 3,853 | $ 3,911 | $ 7,618 | $ 8,105 |